CLINUVEL PHARMACEUTICALS LIMITED (CUV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CUV

CUV - CLINUVEL PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.02
Index: ASX300 | ALL-ORDS

Clinuvel is a biopharmaceutical company that develops and commercialises treatments for patients with genetic, metabolic and life threatening disorders. The company was founded and listed in 2001.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$11.32

20 Feb
2025

0.200

OPEN

$11.55

1.80%

HIGH

$11.55

203,984

LOW

$10.89

TARGET
$19.625 73.4% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CUV: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 71.5 74.6 xxx
DPS (cps) xxx 5.0 5.5 xxx
EPS Growth xxx 15.5% 4.3% xxx
DPS Growth xxx 0.0% 10.0% xxx
PE Ratio xxx N/A 15.1 xxx
Dividend Yield xxx N/A 0.5% xxx
Div Pay Ratio(%) xxx 7.0% 7.4% xxx

Dividend yield today if purchased 3 years ago: 0.23%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.44

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/09 - ex-div 5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx71.5
DPS All xxxxxxxxxxxxxxx5.0
Sales/Revenue xxxxxxxxxxxxxxx88.2 M
Book Value Per Share xxxxxxxxxxxxxxx405.4
Net Operating Cash Flow xxxxxxxxxxxxxxx37.1 M
Net Profit Margin xxxxxxxxxxxxxxx40.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx19.39 %
Return on Invested Capital xxxxxxxxxxxxxxx19.32 %
Return on Assets xxxxxxxxxxxxxxx16.71 %
Return on Equity xxxxxxxxxxxxxxx19.39 %
Return on Total Capital xxxxxxxxxxxxxxx23.59 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx29.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx184 M
Price To Book Value xxxxxxxxxxxxxxx3.79

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx5.6 M
Capex % of Sales xxxxxxxxxxxxxxx6.32 %
Cost of Goods Sold xxxxxxxxxxxxxxx30 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx14 M
Research & Development xxxxxxxxxxxxxxx2 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

30/08/2024

1

Buy

$22.25

96.55%

Clinuvel Pharmaceuticals posted FY24 results that were above Bell Potter's estimates. Revenue forecasts are increased although this is more than offset by increases to operating expenses. More clarity on expenses is expected to come in December with the company's new three-year expense plan.

The results have demonstrated the high margin EPP franchise continues to provide more than enough cash flow to sustain broader R&D investment while maintaining an EBITDA margin of more than 50%, the broker adds.

Buy rating and $22.25 target maintained.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 5.00 cents and EPS of 69.10 cents.
Bell Potter forecasts a full year FY26 dividend of 5.00 cents and EPS of 70.20 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Moelis

31/10/2024

1

Buy

$23.00

103.18%

While updating for both the AGM and the more distant FY24 result, Moelis observes Clinuvel Pharmaceuticals' expansion into the vitiligo treatment market should drive long-term growth, but cautions around significant potential delays in trial timelines.

Revenue growth in FY24 was driven by volume growth in both the EU and the US  for Clinuval's core erythropoietic protoporphyria (EPP) market. 

If trials are successful, commercialisation in the vitiligo market could unlock substantial revenue, with a potential launch by FY28, highlights the analyst.

The broker retains a Buy rating with a $23.00 target, suggesting the market may be undervaluing Clinuvel’s progress in the vitiligo sector. Buy rating.

FORECAST
Moelis forecasts a full year FY25 dividend of 5.60 cents and EPS of 74.30 cents.
Moelis forecasts a full year FY26 dividend of 5.70 cents and EPS of 75.00 cents.
Access Extra Coverage Research History >

CUV STOCK CHART

FNArena News on CUV

1
Rudi’s View: Best Ideas & Conviction Calls

Feb 20 2025 - Rudi's View
2
Rudi’s View: AGL Energy, Bega Cheese, BRG, Harvey Norman, Imdex & Superloop

Feb 06 2025 - Rudi's View
3
Rudi’s View: Cochlear, Guzman y Gomez, SiteMinder, Wesfarmers & Xero

Jan 30 2025 - Rudi's View
4
Rudi’s View: Feb Season’s Best Buys & Key Picks

Jan 23 2025 - Rudi's View
5
Rudi’s View: Best Buys & Convictions For 2025

Jan 16 2025 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
2
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
3
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
4
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
5
CSL Shares Breaking Free

Jul 23 2024 - Technicals
6
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
7
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
8
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
9
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
10
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps